C4 Therapeutics (CCCC) Profit After Tax (2019 - 2026)

C4 Therapeutics' Profit After Tax history runs 8 years deep, the most recent figure standing at -$25.5 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 3.12% year-over-year to -$25.5 million; the TTM figure through Mar 2026 stood at -$104.1 million (down 1.24% YoY), while the FY2025 annual figure was -$105.0 million, changed 0.14% from the prior year.
• Profit After Tax for Q1 2026 stood at -$25.5 million, down from -$20.5 million in the prior quarter.
• The five-year high for Profit After Tax was -$17.7 million in Q2 2024, with the low at -$37.2 million in Q4 2022.
• The 5-year median for Profit After Tax is -$28.4 million (2024), against an average of -$28.9 million.
• The sharpest annual moves came in 2022 and 2024: Profit After Tax tumbled 128.59% in 2022, then surged 50.68% in 2024.
• C4 Therapeutics' Profit After Tax stood at -$37.2 million in 2022, then advanced by 17.38% to -$30.7 million in 2023, then decreased by 13.76% to -$35.0 million in 2024, then jumped by 41.43% to -$20.5 million in 2025, then retreated by 24.48% to -$25.5 million in 2026.
• Business Quant data shows CCCC's Profit After Tax at -$25.5 million in Q1 2026, -$20.5 million in Q4 2025, and -$32.0 million in Q3 2025.